| Characteristic | Orphan | Non-orphan |
|---|---|---|
| - | - | - |
| - | - | - |
| - | - | - |
| - | - | - |
| - | - | - |
The chart is not accessible to screen readers. Please switch to the table view to access the data.
Download
Source
Release date
April 2019
Region
United States
Survey time period
2014 to 2018
Supplementary notes
* Including the top 100 products.
* Products that have orphan and non-orphan drug
designations and are expected to generate less than 50% of their sales in 2018 and 2024 from
their orphan-designated indication/s, are excluded from this statistic. This has led to the exclusion
of therapies such as Avastin, Opdivo, Enbrel, Herceptin, Humira and Remicade.
Citation formats









